Tag Archive for: Optimum

Optimum Strategic Communications Expands Team with Appointment of Shabnam Bashir

/in

08 January 2020, London, UK: Optimum Strategic Communications (Optimum), the international strategic healthcare communications firm, today announced the appointment of Shabnam Bashir.  Shabnam brings 10 years of experience advising UK and international companies ranging from start-ups to large public organisations across a range of sectors advising on strategy, crises management, IPO and M&A transactions. Shabnam […]

Read more

Owkin Teams up with NVIDIA and King’s College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning

/in

PARIS and NEW YORK, Dec. 2, 2019 /PRNewswire/ — Owkin, which is developing Federated Learning and AI technologies to advance medical research, announces it is teaming up with technology company NVIDIA and King’s College London (KCL) to deliver Federated Learning in the healthcare and life sciences sector. The King’s College London Medical Imaging and AI Centre for Value Based Healthcare (AI4VBH) is […]

Read more

Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD

/in

Results to Inform Development Plan and Dose Selection for Phase 3 LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as […]

Read more

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

/in

LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (“COPD”) at CHEST Annual Meeting (“CHEST”) on Monday, October 21, 2019 […]

Read more

ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank

/in

The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16). Read more

Read more